PTC Therapeutics | PTCT - Debt


PTC Therapeutics reported $286.94M in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
Acadia Pharmaceuticals USD 50.79M 1.39M Mar/2026
Alnylam Pharmaceuticals USD 1.27B 5.33M Mar/2026
Amgen USD 57.32B 2.72B Mar/2026
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
Biogen USD 8.09B 1.53B Jun/2026
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Cytokinetics USD 1.29B 4.48M Mar/2026
Daiichi Sankyo JPY 300.48B 99.34B Mar/2026
Enanta Pharmaceuticals USD 1.35M 0 Dec/2024
Gilead Sciences USD 22.17B 2.76B Mar/2026
Incyte USD 38.27M 1.16M Jun/2026
Ionis Pharmaceuticals USD 1.91B 425.5M Jun/2026
Ironwood Pharmaceuticals USD 583.99M 14.83M Dec/2024
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
Novartis USD 49.01B 2.02B Jun/2026
Pfizer USD 63.19B 536M Jun/2026
PTC Therapeutics USD 286.94M 2.42B Mar/2026
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Roche Holding CHF 33.03B 1.41B Jun/2025
Sangamo BioSciences USD 0 0 Jun/2022
Sarepta Therapeutics USD 1.04B 3.08M Mar/2026
TG Therapeutics USD 754.44M 884K Jun/2026
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Vertex Pharmaceuticals USD 1.98B 8.9M Jun/2026
Xencor USD 175.16M 12.58M Mar/2026